LENVIMA™ (lenvatinib) Demonstrated an Unprecedented Improvement in Progression-Free Survival (PFS) and a Statistically Significant Overall Response Rate in Patients with Radioactive Iodine-refractory Differentiated Thyroid Cancer (RAI-R DTC)

MISSISSAUGA, ON, April 12, 2016 /CNW/…